STAAR Surgical experienced a failed merger with Alcon and substantial financial deterioration with revenue declining nearly 24% year-over-year.
The termination of the Alcon merger agreement represents a significant strategic setback that likely created uncertainty about the company's growth trajectory and market position. The accompanying financial decline across key metrics suggests operational challenges that may have contributed to or resulted from the failed transaction, potentially leaving STAAR in a weakened competitive position.
STAAR's financial performance deteriorated meaningfully across most key metrics, with revenue declining nearly 24% to $239.4M and gross profit falling by a similar magnitude to $182.4M. The company reduced capital expenditures substantially from $23.4M to $5.8M, suggesting constrained investment capacity or strategic pullback. Balance sheet strength also weakened with total assets declining 11.4% and stockholders' equity dropping 13.4%, painting a picture of a company under financial stress following the failed merger attempt.
Capex reduced 75.1% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Receivables declined — improved collection efficiency or conservative revenue recognition.
R&D spending cut 25.8% — could signal cost discipline or concerning reduction in innovation investment.
Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.
Revenue softened 23.7% — monitor whether this is cyclical or structural.
Current assets declined 15.3% — monitor working capital adequacy and short-term liquidity.
Equity decreased 13.4% — buybacks or losses reducing book value, monitor solvency ratios.
Total assets contracted 11.4% — asset sales, write-downs, or balance sheet optimization underway.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →